Tenax Therapeutics (TENX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of seven director nominees for the board, including June Almenoff, Michael Davidson, Declan Doogan, Christopher Giordano, Robyn Hunter, Gerald Proehl, and Stuart Rich.
Ratification of Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is on the agenda.
The proxy may vote on other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Seven individuals are nominated for election to the board, representing a mix of medical, executive, and financial expertise.
Audit committee and external auditor matters
Cherry Bekaert LLP is recommended for ratification as the independent registered public accounting firm for the next fiscal year.
Latest events from Tenax Therapeutics
- Annual meeting to elect directors, ratify auditor, and review governance and compensation.TENX
Proxy filing22 Apr 2026 - Seeks to raise up to $300 million for late-stage cardiopulmonary drug development via shelf registration.TENX
Registration filing24 Mar 2026 - LEVEL trial enrollment finished early; global expansion and Q3 results expected.TENX
Leerink Global Healthcare Conference 202610 Mar 2026 - Levosimendan targets a major unmet need in PH-HFPEF, advancing in late-stage trials.TENX
Corporate presentation10 Mar 2026 - LEVEL and LEVEL-2 trials advanced, net loss widened, cash reserves support operations through 2027.TENX
Q4 202510 Mar 2026 - Levosimendan's Phase III program advances with strong clinical data and broad market potential.TENX
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026 - Phase 3 trials for oral levosimendan in PH-HFpEF expand, with strong funding and patent protection.TENX
Leerink’s Global Healthcare Conference 202526 Dec 2025 - Phase III oral therapy for PH-HFpEF shows promise, with strong clinical and market potential.TENX
24th Annual Needham Virtual Healthcare Conference23 Dec 2025 - Registering resale of 50M+ shares post-$100M raise to fund Phase 3 drug development.TENX
Registration Filing16 Dec 2025